TY - JOUR
T1 - The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ
AU - Semeraro, Michaela
AU - Adam, Julien
AU - Stoll, Gautier
AU - Louvet, Emilie
AU - Chaba, Kariman
AU - Poirier-Colame, Vichnou
AU - Sauvat, Allan
AU - Senovilla, Laura
AU - Vacchelli, Erika
AU - Bloy, Norma
AU - Humeau, Juliette
AU - Buque, Aitziber
AU - Kepp, Oliver
AU - Zitvogel, Laurence
AU - André, Fabrice
AU - Mathieu, Marie Christine
AU - Delaloge, Suzette
AU - Kroemer, Guido
N1 - Publisher Copyright:
© 2016 Taylor & Francis Group, LLC.
PY - 2016/10/2
Y1 - 2016/10/2
N2 - In a series of 248 tumor samples obtained from image-guided biopsies from patients diagnosed with ductal carcinoma in situ of the breast, we attempted to identify biomarkers that predict microinfiltration at definitive surgery or relapse during follow-up. For this, we used immunohistochemical methods, followed by automated image analyses, to measure the mean diameter of nuclei (which correlates with ploidy), the phosphorylation of eukaryotic initiation factor 2α (eIF2α, which reflects endoplasmic reticulum stress) as well as the density and ratio of CD8+ cytotoxic T lymphocytes and FOXP3+ regulatory T cells. The median nuclear diameter of malignant cells correlated with eIF2α phosphorylation (in cancerous tissue), which in turn correlated with the density of the CD8+ infiltrate and the CD8+/FOXP3 ratio (both in cancerous and the adjacent non-cancerous parenchyma). Neither microinfiltration nor lymph node involvement was associated with the probability of relapse. Both correlated positively with the CD8+/FOXP3 ratio in the malignant area. In contrast, relapse was associated with a paucity of the CD8+ infiltrate as well as an unfavorable CD8+/FOXP3 ratio, both in malignant and non-malignant parenchyma. The combined analysis of the CD8+/FOXP3 ratio in cancerous and non-cancerous tissues revealed a significant impact of their interaction on the probability of relapse, but not on the presence of microinfiltration or lymph node metastasis. Altogether, these results support the idea of an immunosurveillance system that determines the risk of relapse in ductal carcinoma in situ of the breast.
AB - In a series of 248 tumor samples obtained from image-guided biopsies from patients diagnosed with ductal carcinoma in situ of the breast, we attempted to identify biomarkers that predict microinfiltration at definitive surgery or relapse during follow-up. For this, we used immunohistochemical methods, followed by automated image analyses, to measure the mean diameter of nuclei (which correlates with ploidy), the phosphorylation of eukaryotic initiation factor 2α (eIF2α, which reflects endoplasmic reticulum stress) as well as the density and ratio of CD8+ cytotoxic T lymphocytes and FOXP3+ regulatory T cells. The median nuclear diameter of malignant cells correlated with eIF2α phosphorylation (in cancerous tissue), which in turn correlated with the density of the CD8+ infiltrate and the CD8+/FOXP3 ratio (both in cancerous and the adjacent non-cancerous parenchyma). Neither microinfiltration nor lymph node involvement was associated with the probability of relapse. Both correlated positively with the CD8+/FOXP3 ratio in the malignant area. In contrast, relapse was associated with a paucity of the CD8+ infiltrate as well as an unfavorable CD8+/FOXP3 ratio, both in malignant and non-malignant parenchyma. The combined analysis of the CD8+/FOXP3 ratio in cancerous and non-cancerous tissues revealed a significant impact of their interaction on the probability of relapse, but not on the presence of microinfiltration or lymph node metastasis. Altogether, these results support the idea of an immunosurveillance system that determines the risk of relapse in ductal carcinoma in situ of the breast.
KW - Cytotoxic T cells
KW - hyperploidy
KW - immunogenic cell death
KW - immunosuppressive regulatory T cells
KW - intraductal carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84990895537&partnerID=8YFLogxK
U2 - 10.1080/2162402X.2016.1218106
DO - 10.1080/2162402X.2016.1218106
M3 - Article
AN - SCOPUS:84990895537
SN - 2162-4011
VL - 5
JO - OncoImmunology
JF - OncoImmunology
IS - 10
ER -